Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 11 to 20 of 728

TitleReference numberPublishedLast updated
Tirzepatide for treating type 2 diabetesTA924
Mirikizumab for treating moderately to severely active ulcerative colitisTA925
Baricitinib for treating severe alopecia areataTA926
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)TA923
Ruxolitinib for treating polycythaemia veraTA921
Daridorexant for treating long-term insomniaTA922
Rimegepant for treating migraineTA919
Tofacitinib for treating active ankylosing spondylitisTA920
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA927
Bimekizumab for treating axial spondyloarthritisTA918

Results per page

  1. 10
  2. 25
  3. 50
  4. All